Overview

Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers

Status:
Unknown status

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

Raltegravir is the first of a new antiretroviral class. A better profile of metabolic toxicity is expected. In order to better define its effects, without interference with other drugs, a study on healthy volunteers is warranted.

Phase:

Phase 1

Details

Lead Sponsor:

Hospital Clinic of Barcelona

Treatments:

Raltegravir Potassium